CD274 and neoplasm: First, we targeted PD-L1, an immunecheckpoint expressed in tumor microenvironment that suppresses cytotoxicT cell function. We generated a PD-L1-targetingLIPTAC by incorporating anti-PD-L1 Atezolizumab (Atz) Fab with 142F1 scFv.